Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/15/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Andy M. Trotti III

Wrong Dr. Andy M. Trotti III?

Senior Mbr Radonc

Phone: (813) ***-****  
Moffitt Cancer Center
H. Lee Cancer Center & Research Institute 12902 Magnolia Drive
Tampa , Florida 33612
United States

Company Description: Located in Tampa, Moffitt is one of only 45 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in...   more

Employment History

  • Physician
    Moffitt Cancer Center
  • Director of Radiation Oncology Clinical Research
    Moffitt Cancer Center
  • Associate Professor and Director of Clinical Research In Radiation Oncology
    University of South Florida's H. Lee Moffitt Cancer Center
  • Associate Professor of Medicine
    University of South Florida College of Medicine

Board Memberships and Affiliations


  • MD
  • M.D.
60 Total References
Web References
HPV Questions & News - Topic, 16 June 2010 [cached]
With the rising incidence of HPV-related oropharynx cancers, it will soon be the predominant type of cancer in the oral or head and neck region, according to Andy Trotti, MD, director of radiation oncology clinical research, H. Lee Moffitt Cancer Center & Research Institute, in Tampa, Fla.
“We should be focusing on HPV-related oropharyngeal cancer because it will dominate the field of head and neck cancers for many years,†he said during an interview with HemOnc Today . “It is certainly an important population for which to continue to conduct research.â€
H. Lee Moffitt Cancer Center & Research Institute, 27 May 2008 [cached]
Andy M. Trotti, MDH. Lee Moffitt Cancer Center & Research Institute
Andy M. Trotti, MD
Andy M. Trotti, MD
Andy M. Trotti, MD
Andy M. Trotti, MD
Calvin D, Hammond M, Pajak T, Trotti A, Meredith R, Rotman M, Jones C, Byhardt R, Demas W, Ang K, Fu K. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial.Am J Clin Oncol.2007 Aug;30(4):406-419.Pubmed ID: 17762442
Trotti A, Colevas A, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology.J Clin Oncol.2007 Nov 10;25(32):5121-5127.Pubmed ID: 17991931
Trotti A, Pajak T, Gwede C, Paulus R, Cooper J, Forastiere A, Ridge J, Watkins-Bruner D, Garden A, Ang K, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.Lancet Oncol.2007 Jul;8(7):613-624.Pubmed ID: 17543584
Chen Y, Trotti A, Coleman C, Machtay M, Mirimanoff R, Hay J, O'brien P, El-Gueddari B, Salvajoli J, Jeremic B. Adverse event reporting and developments in radiation biology after normaltissue injury: International Atomic Energy Agency consultation.Int J Radiat Oncol Biol Phys.2006 Apr 1;64(5):1442-51.Epub 2.Pubmed ID: 16414207
Forastiere A, Trotti A, Pfister D, Grandis J. Head and neck cancer: recent advances and new standards of care.J Clin Oncol.2006 Jun 10;24(17):2603-2605.Pubmed ID: 16763271
Wood G, Casey L, Trotti A. Skin changes.Cancer Treat Res.2006;128:171-181.Pubmed ID: 16335018
Ang K, Harris J, Garden A, Trotti A, Jones C, Carrascosa L, Cheng J, Spencer S, Forastiere A, Weber R. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.J Clin Oncol.2005 May 1;23(13):3008-3015.Pubmed ID: 15860857
Soares H, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments.JAMA.2005 Feb;293(8):970-978.Pubmed ID: 15728168
Trotti A, Bentzen S. The need for adverse effects reporting standards in oncology clinical trials.J Clin Oncol.2004;22:19-22.Pubmed ID: 14657230
Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak T, Fleming T, Henke M, Bourhis J, Rosenthal D, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang K. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.Int J Radiat Oncol Biol Phys.2004;58(3):674-681.Pubmed ID: 14967419
Trotti A, Bellm L, Epstein J, Frame D, Fuchs H, Gwede C, Komaroff E, Nalysnyk L, Zilberberg M. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.Radiother Oncol.2003;66(3):253-262.Pubmed ID: 12742264
Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman C, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.Semin Radiat Oncol.2003;13(3):176-181.Pubmed ID: 12903007
Gwede C, Johnson D, Daniels S, Trotti A. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.J Oncol Manag.2002;11(2):15-21.Pubmed ID: 11989815
Rose-Ped A, Bellm L, Epstein J, Trotti A, Gwede C, Fuch H. Complications of radiation therapy for head and neck cancer.The patient's perspective.Cancer Nurs.2002;25(6):461-467.Pubmed ID: 12464838
Trotti A. The evolution and application of toxicity criteria.Semin Radiat Oncol.2002;12(1):1-3.Pubmed ID: 11917276
Kim C, Yeatman T, Coppola D, Trotti A, Williams B, Barthel J, Dinwoodie W, Karl R, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation.
Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormic B, Morris M, Rich T, Shipley W, Curran W. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.Int J Radiat Oncol Biol Phys.2000;47(1):13-47.Pubmed ID: 10758303
Trotti A. Toxicity in head and neck cancer: a review of trends and issues.Int J Radiat Oncol Biol Phys.2000;47(1):1-12.Pubmed ID: 10758302
Flood W, Lee D, Trotti A, Spencer S, Murphy B, Khuri F, DeConti R, Wheeler R, Forastiere A. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.Semin Rad Oncol.1999;9(2) Suppl 1:61-69.Pubmed ID: 10210542
Johnson D, Roberts C, Trotti, III A, Greenberg H. Professional satisfaction among radiation therapists: a regional survey.Radiation Therapist.1998;7(1):103-110.
Sekharam M, Trotti, III A, Cunnick J, Wu J. Supression of fibroblast cell cycle progression in G1 phase by N-acetylcysteine.
Trotti A, Johnson D, Gwede C, Casey L, Sauder B, Cantor A. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI) . Int J Radiat Oncol Biol Phys.1998;42(2):257-261.Pubmed ID: 9788402
Trotti, III A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial.
Balducci L, Trotti, III A. Organ preservation: an effective and safe form of cancer treatment.Clin Geriatr Med.1997;13(1):185-201.Pubmed ID: 8995107
Cruse C, Reintgen D, Glass F, Messina J, Trotti, III A, DeConti R. Clinical practice guidelines: neuroendocrine tumors of the skin.Cancer Control.1997;4:258-260.
Futran N, Trotti, III A, Gwede C. Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations.
Trotti, III A. Toxicity antagonists in cancer therapy.Curr Opin Oncol.1997;9:569-578.Pubmed ID: 9370079
Johnson D, Casey L, Gwede C, Friedland J, Trotti, III A. 1996;850-851.
Vaidynathan M, Clarke L, Velthuizen R, Phuphanich S, Bensaid A, Hall L, Bezdek J, Greenberg H, Trotti, III A, Silbiger M. Comparison of supervised MRI segmentation methods for tumor volume determination during therapy.
Gupta S, Spiers A, Saba H, Moscinski L, Lyman G, Diaz J, Trotti, III A, Ridley M, Endicott J, Sanderson R. Extranodal lymphomas of the head and neck (ELHN): A six-year survey.Blood.1993;82: 2245.
Trotti III A, Klotch D, Endicott J, Ridley M, Greenberg H. A prospective trial of accelerated radiotherapy in the postoperative treatment of high risk squamous cell carcinoma of the head and neck.Int J Radiat Oncol Biol Phys.1993;26(1):13-21.Pubmed ID: 8482619
Andy M. Trotti, MD
Education & Training:
Andy M. Trotti, MD
Research Interests:
As one of the longest serving Moffitt physicians, Dr. Trotti is recognized for expertise in head and neck and cutaneous malignancies, and the adverse effects of cancer treatment.He has conducted original and collaborative group clinical trials in head and neck cancer at the Cancer Center for more than 17 years.
Under his leadership, Moffitt became a member of the National Cancer Institute-sponsored Radiation Therapy Oncology Group (RTOG) in 1990 and continues today as one of a select group of active full members.Dr. Trotti serves as institutional principal investigator for RTOG studies.Several of Dr.Trotti's original pilot studies conducted at Moffitt in the areas of fractionation, toxicity interventions, and combined modality therapy have advanced to become national multicenter trials.Dr. Trotti is co-chair of the RTOG Head and Neck Committee.Under his guidance, several of his radiation oncology colleagues at Moffitt have participated in leadership roles within RTOG, including the Quality of Life Committee, Outcomes Committee, Special Populations Committees, and Research Associates Committee.
As part of the effort to measure outcomes, Darlene Johnson, MBA, and Dr. Trotti developed and validated a radiation-specific quality of life tool currently in use in two national RTOG trials.
Dr. Trotti and colleague Dr. Javier Torres-Roca were recently awarded a pilot grant to study genomic predictors of radiosensitivity in RTOG populations.
Dr. Trotti is co-chair of the Health Services Research (HSR) Committees for both the American Society of Therapeutic Radiology and Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO).Dr. Trotti has a unique area of expertise: the recognition, reporting, prevention, and management of the adverse effects of cancer treatment.Dr Trotti assisted the NCI in creating the current NCI
New England Partners - News - Intrabiotics 7-26-00, 26 July 2000 [cached]
Dr. Andy Trotti , Associate Professor and Director of Clinical Research in Radiation Oncology at the University of South Florida's H. Lee Moffitt Cancer Center , said , Oral mucositis is a serious medical problem for patients receiving radiotherapy for head and neck cancers.Mucositis greatly impacts nutrition and quality of life.It also represents a dose and schedule-limiting toxicity of radiotherapy.There is an urgent need to reduce the side effects of cancer therapy , thereby improving the patient's well-being and allowing clinicians to administer more effective treatment regimens..Dr. Trotti is co-chair of the Phase III study steering committee in addition to being an investigator in the study and co-chair of the Radiation Therapy Oncology Group's Head and Neck Committee.
H.Lee Moffitt Cancer Center - News, 15 Feb 2000 [cached]
Andrew Trotti, III, M.D., Associate Professor of Medicine at the University of South Florida College of Medicine and a radiation oncologist at Moffitt, will participate in a presentation of the NCCN practice guidelines for head and neck cancers.
Other People with the name "Trotti":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.